Segment Information (Tables)

6 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Disaggregation of Revenue [Table Text Block]

	Three Months Ended December 31,
(in millions)	2020		2019
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	37,040	$	35,501
Nuclear and Precision Health Solutions	196		213
Pharmaceutical segment revenue	37,236		35,714
Medical distribution and products (3)	3,729		3,498
Cardinal Health at-Home Solutions	581		525
Medical segment revenue	4,310		4,023
Total segment revenue	41,546		39,737
Corporate (4)	(5)		(2)
Total revenue	$	41,541	$	39,735

	Six Months Ended December 31,
(in millions)	2020		2019
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	71,956	$	68,713
Nuclear and Precision Health Solutions	392		429
Pharmaceutical segment revenue	72,348		69,142
Medical distribution and products (3)	7,167		6,944
Cardinal Health at-Home Solutions	1,100		996
Medical segment revenue	8,267		7,940
Total segment revenue	80,615		77,082
Corporate (4)	(9)		(6)
Total revenue	$	80,606	$	77,076

(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."

(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.

(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue from External Customers by Geographic Areas [Table Text Block]

The following tables present revenue by geographic area:

	Three Months Ended December 31,
(in millions)	2020		2019
United States	$	40,360	$	38,670
International	1,186		1,067
Total segment revenue	41,546		39,737
Corporate (1)	(5)		(2)
Total revenue	$	41,541	$	39,735

	Six Months Ended December 31,
(in millions)	2020		2019
United States	$	78,336	$	74,980
International	2,279		2,102
Total segment revenue	80,615		77,082
Corporate (1)	(9)		(6)
Total revenue	$	80,606	$	77,076

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment

The following tables present segment profit by reportable segment and Corporate:

	Three Months Ended December 31,
(in millions)	2020		2019
Pharmaceutical	$	413	$	462
Medical	236		195
Total segment profit	649		657
Corporate	(188)		(323)
Total operating earnings	$	461	$	334

	Six Months Ended December 31,
(in millions)	2020		2019
Pharmaceutical	$	815	$	860
Medical	466		365
Total segment profit	1,281		1,225
Corporate	(1,444)		(6,155)
Total operating loss	$	(163)	$	(4,930)

Assets by Reportable Segment

The following table presents total assets for each reportable segment and Corporate at:

(in millions)	December 31, 2020		June 30, 2020
Pharmaceutical	$	23,567	$	22,398
Medical	15,259		14,691
Corporate	5,893		3,677
Total assets	$	44,719	$	40,766